Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 643
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT05154370 CNRID — China National Registry of Neuro-Inflammatory Diseases |
Intravenous steroid | SEP | À vérifier | RECRUITING | En attente / non publié | Beijing Tiantan Hospital | China · Beijing Tiantan Hospital, Beijing, China | 2021-12-15 → 2026-11-01 | Ouvrir |
| NCT04838886 The Effect of Telerehabilitation Based Pilates Training in Multiple Scl… |
The Effect of Telerehabilitation … | SEP | Non applicable | COMPLETED | En attente / non publié | Gazi University | Turkey (Türkiye) · Gazi University, Faculty of Health… | 2021-04-15 → 2022-05-25 | Ouvrir |
| NCT00001669 A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II P… |
rhIGF-1 (CEP-151) | SEP | Phase 2 | COMPLETED | En attente / non publié | National Institute of Neurologica… | United States · National Institute of Neurological Di… | 1997-07 → 2000-04 | Ouvrir |
| NCT04201470 AMIS — Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis |
AMIS — Serum Neurofilaments and G… | SEP | Non applicable | COMPLETED | En attente / non publié | University Hospital, Montpellier | France · CHU Montpellier, Montpellier, France | 2019-12-09 → 2022-05-23 | Ouvrir |
| NCT04561557 CARTinNS — Safety and Efficacy of CT103A Cells for Relapsed/Refractory … |
CT103A cells | SEP | Phase 1 | RECRUITING | En attente / non publié | Tongji Hospital | China · Tongji Hospital affiliated to Tongji Medical … | 2020-09-22 → 2027-05-31 | Ouvrir |
| NCT05147532 SMARTinMS — Remyelination in Multiple Sclerosis: a PET-MR Longitudinal … |
PET-MRI with [18F]-Florbetaben an… | SEP | Non applicable | UNKNOWN | En attente / non publié | Assistance Publique - Hôpitaux de… | France · CIC Neurosciences - Hôpital Pitié Salpêtrièr… | 2022-01-24 → 2024-05 | Ouvrir |
| NCT04539002 Aerobic Exercise for Remyelination in Multiple Sclerosis |
Aerobic Exercise for Remyelinatio… | SEP | Phase 1/2 | COMPLETED | En attente / non publié | Oregon Health and Science Univers… | United States · Oregon Health & Science University, P… | 2021-04-29 → 2025-03-27 | Ouvrir |
| NCT06065670 ReINFORCE — Assessing Changes in Multi-parametric MRI in Patients With … |
Clemastine Fumarate | SEP | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | University of California, San Fra… | United States · Sandler Neurosciences Building, Neuro… | 2026-09-15 → 2028-10-30 | Ouvrir |
| NCT01772199 Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects W… |
GSK239512 | SEP | Phase 2 | COMPLETED | En attente / non publié | GlaxoSmithKline | Bulgaria, Canada, Czechia, Germany, Spain, Sweden, Uk… | 2013-02 → 2014-09 | Ouvrir |
| NCT05338450 RESTORE — Clemastine Fumarate as Remyelinating Treatment in Internuclea… |
Clemastine Fumarate | SEP | Phase 3 | TERMINATED | En attente / non publié | University of California, San Fra… | Netherlands · Amsterdam UMC, location VUmc, Amsterdam… | 2022-08-30 → 2025-08-15 | Ouvrir |
| NCT01085318 Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Tr… |
Rebif | SEP | Phase 4 | COMPLETED | En attente / non publié | EMD Serono | United States · EMD Serono, Inc., Rockland, United St… | 2010-06-30 → 2012-03-31 | Ouvrir |
| NCT05418010 Natalizumab for the Treatment of People With Inflammatory Demyelination… |
Tyruko Injectable Product | SEP | Phase 2 | RECRUITING | En attente / non publié | Queen Mary University of London | United Kingdom · Royal London Hospital, London, Unite… | 2022-12-01 → 2027-10-31 | Ouvrir |
| NCT01307332 iCAMMS-IST — Advanced MRI Measures of Repair in Alemtuzumab Treated Pat… |
MabCampath-1h | SEP | Phase 3 | COMPLETED | En attente / non publié | University of British Columbia | Canada · University of British Columbia Hospital, Van… | 2011-03 → 2018-09-28 | Ouvrir |
| NCT04767698 Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multip… |
Belimumab | SEP | Phase 2 | TERMINATED | En attente / non publié | Johns Hopkins University | United States · Johns Hopkins University, Baltimore, … | 2021-10-01 → 2022-05-10 | Ouvrir |
| NCT06159712 CoSHEDRMS — Comparative Study of High-Efficacy Disease Modifying Treatm… |
CoSHEDRMS — Comparative Study of … | SEP | Non applicable | UNKNOWN | En attente / non publié | University of Aarhus | Denmark · Aarhus University, Aarhus, Denmark | 2023-11-27 → 2025-11 | Ouvrir |
| NCT04175834 PRECEPT — Comparing Risk and Severity of IRRs in Patients Premedicated … |
cetrizine | SEP | Phase 3 | COMPLETED | En attente / non publié | Providence Health & Services | United States · Providence Neurological Specialties W… | 2020-02-05 → 2022-05-13 | Ouvrir |
| NCT03138525 Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis |
Immune Profiling During Ocrelizum… | SEP | À vérifier | COMPLETED | En attente / non publié | Brigham and Women's Hospital | United States · Brigham and Women's Hospital, Boston,… | 2017-06-20 → 2019-12-20 | Ouvrir |
| NCT01247324 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in… |
Interferon beta-1a | SEP | Phase 3 | COMPLETED | En attente / non publié | German University in Cairo | United States, Argentina, Australia, Austria, Belgium… | 2011-08-31 → 2022-12-31 | Ouvrir |
| NCT07597668 A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and … |
RPH-035 | SEP | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | R-Pharm | Russia · Federal State Budgetary Educational Institut… | 2025-04-16 → 2027-11-24 | Ouvrir |
| NCT05779449 Pre-Pro-MS — Targeting the Gut Dysbiosis to Treat Inflammation-driven S… |
peripheral blood withdrawal | SEP | Non applicable | UNKNOWN | En attente / non publié | Neuromed IRCCS | Italy · IRCCS INM-Neuromed, Pozzilli, Italy | 2023-07-26 → 2026-05-01 | Ouvrir |
| NCT05877963 ENHANCE — Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) … |
Ublituximab | SEP | Phase 3 | RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States, Poland · TG Investigational Site, Farm… | 2023-06-13 → 2027-01-21 | Ouvrir |
| NCT04130997 An Extension Study of Ublituximab in Participants With Relapsing Multip… |
Ublituximab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States, Belarus, Croatia, Georgia, Poland, Rus… | 2019-11-18 → 2032-05-31 | Ouvrir |
| NCT06143514 PROVIDE — A Study Evaluating the Presence and Concentration of BRIUMVI™… |
PROVIDE — A Study Evaluating the … | SEP | À vérifier | RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States · PROVIDE Virtual Research Coordination… | 2024-03-26 → 2026-10-31 | Ouvrir |
| NCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Rad… |
Ublituximab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | TG Therapeutics, Inc. | Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, G… | 2025-07-09 → 2028-12-31 | Ouvrir |
| NCT07783269 ALLNEW — A Basket Study of CTA313 in Participants With Active Autoimmun… |
CTA313 UCAR T Cell Infusion | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Imviva Bio | Non communiqué | 2026-12 → 2029-09 | Ouvrir |